A prognostic score for chronic myeloid leukemia


A prognostic score for chronic myeloid leukemia

A prognostic score for chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that is characterized by uncontrolled myeloid cell divisions in the bone marrow. The disease is caused by a reciprocal translocation between chromosomes and is associated with the Philadelphia chromosome.

Specialists of the Research Laboratory of Immuno-Oncology were the first in the world to create a prognostic score for predicting failure to achieve a complete cytogenetic response in patients with chronic myeloid leukemia in the chronic phase.

The study was conducted in 73 patients who did not have a complete response to treatment before starting the third-line therapy. The score includes data on the age of the patient at the time of the start of the third-line therapy, indicators of cytogenetic response to the first-, second- and before the third-line therapy.

Three risk groups for failure to achieve the optimal complete cytogenetic response were formed and ranked by score.

Further, the researchers validated the score in an independent sample (41 patients), which made it possible to confirm the possibility of a favorable course of the disease in the low-risk group.

These unique data make us approach this complex disease from a different angle and indicate that its treatment should be based on evidence-based approaches, risk stratification and become increasingly personalized.


22.12.2022

Back to the list